Diagnosis and treatment of vascular cognitive impairments
https://doi.org/10.21518/2079-701X-2021-2-45-54
Abstract
Vascular brain diseases are one of the leading causes of death and disability in developed countries. Along with acute disorders of cerebral circulation, chronic cerebrovascular disorders are of great medical and social importance, one of the main clinical manifestations is vascular cognitive impairments. The article discusses the pathogenetic and clinical variants of vascular cognitive impairments, presents their modern classification and approaches to diagnosis. The importance of the earliest possible diagnosis of vascular cognitive impairments is due to the fact that they can be one of the first manifestations of cerebrovascular insufficiency, before the development of clinically obvious strokes or cardiovascular diseases in general. Early diagnosis of vascular cognitive impairments is necessary both for the prevention of vascular and neurodegenerative dementia and for the prevention of strokes and other acute vascular episodes. A clinical example of non-stroke formation of mild vascular cognitive impairment is presented. Signs of cognitive impairments typical of chronic cerebrovascular insufficiency, such as a slowdown in the rate of mental activity and disorders of frontal executive functions in combination with behavioral and emotional disorders, are described. The article discusses the issues of treatment of vascular cognitive impairments, which should be comprehensive and include the correction of the underlying vascular disease, non-drug (regular physical activity, smoking cessation, cognitive training) and drug treatment methods aimed at improving cognitive functions. Possibilities of modern neuroprotective and symptomatic therapy of cognitive disorders, the place of EGb 761® in the treatment of vascular cognitive impairments are shown.
About the Authors
D. A. Grishina
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Dinara A. Grishina, Cand. of Sci. (Med.), Assistant of the Department of Nervous Diseases and Neurosurgery of the Medical Faculty
11, Bldg. 1, Rossolimo St., Moscow, 119021
A. B. Lokshina
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Anastasia B. Lokshina, Cand. of Sci. (Med.), Assistant of the Department of Nervous Diseases and Neurosurgery of the Medical Faculty
11, Bldg. 1, Rossolimo St., Moscow, 119021
References
1. Parfenov V.A. Dyscirculatory encephalopathy and vascular cognitive disorders. Moscow: IMA-PRESS; 2017. 128 p. (In Russ.) Available at: https://docplayer.ru/78358480-V-a-parfenov-discirkulyatornaya-encefalopatiyai-sosudistye-kognitivnye-rasstroystva.html.
2. Parfenov V.A., Zakharov V.V., Preobrazhenskaya I.S. Cognitive disorders. Moscow: Remedium; 2014. 192 p. (In Russ.) Available at: https://kniga-cici.info/5004/Захаров_Парфенов_Преображенская_Когнитивные_расстройства.pdf.
3. Yakhno N.N., Zakharov V.V., Lokshina A.B., Koberskaya N.N., Mkhitaryan E.A. Dementia: Guidance for Doctors. Moscow: MEDpress-inform; 201. 272 p. (In Russ.) Available at: https://03book.ru/upload/iblock/987/415_Demencija_Jahno.pdf.
4. Dickerson B., Atri A. (eds) Dementia: Comprehensive Principles and Practice. Oxford University Press; 2014. 688 p. doi: 10.1093/med/9780199928453.001.0001.
5. Ankolekar S., Geeganage C., Anderton P., Hogg C., Bath P.M. Clinical Trials for Preventing Post Stroke Cognitive Impairment. J Neurol Sci. 2010;299(1–2):168–174. doi: 10.1016/j.jns.2010.08.052.
6. Skrobot O.A., O’Brien J., Black S., Chen C., DeCarli C., Erkinjuntti T. et al. The Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2017;13(6):624–633. doi: 10.1016/j.jalz.2016.10.007.
7. Sachdev P., Kalaria R., O’Brien J., Skoog I., Alladi S., Black S.E. et al. Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement. Alzheimer Dis Assoc Disord. 2014;28(3):206–218. doi: 10.1097/WAD.0000000000000034.
8. The ICD-10 classification of mental and behavioral disorders. Diagnostic criteria for research. Geneva: World Health Organization; 1993. 263 p. Available at: https://who.int/classifications/icd/en/GRNBOOK.pdf.
9. Hachinski V.C., Bowler J.V. Vascular Dementia. Neurology. 1993;43(10): 2159–2160. doi: 10.1212/wnl.43.10.2159-a.
10. Gorelick P.B., Scuteri A., Black S.E., Decarli C., Greenberg S.M., Iadecola C. et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–2713. doi: 10.1161/STR.0b013e3182299496.
11. Levine D.A., Langa K.M. Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications. Neurotherapeutics. 2011;8(3):361–373. doi: 10.1007/s13311-011-0047-z.
12. Shavlovskaya O.A., Lokshina A.B., Grishina D.A. Prevention of Cognitive Impairment in Patients with Cerebrovascular Disease. Profilakticheskaya meditsina = The Russian Journal of Preventive Medicine. 2019;(2):92–97. (In Russ.) doi: 10.17116/profmed20192202189.
13. Yakhno N.N., Zakharov V.V., Lokshina A.B. Moderate Cognitive Impairment Syndrome in Cerebral Vascular Insufficiency. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2005;105(2): 13–17. (In Russ.) Available at: http://www.scopus.com/inward/record.url?eid=2-s2.0-17144396683&partnerID=MN8TOARS.
14. Zakharov V.V., Lokshina A.B. Practical Algorithms for Management of Patients with Chronic Cerebral Ischemia. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2019;15(19):24–28. (In Russ.) doi: 10.33978/2307-3586-2019-15-19-24-28.
15. Yakhno N.N., Koberskaya N.N., Zakharov V.V., Grishina D.A., Lokshina A.B., Mkhitaryan E.A. et al. The Influence of Age, Gender, Comorbide Cardiovascular and Emotional Factors on Subjective Cognitive Decline. Nevrologicheskiy Zhurnal = Neurological Journal. 2018;23(4):184–189. (In Russ) Available at: http://www.medlit.ru/journalsview/nevrojournal/view/journal/2018/issue-4/335-vliyanie-vozrastnyh-gendernyh-komorbidnyh-serdechno-sosudistyh-i-emocional-nyh-faktorov-na-sub-ektivnoekognitivnoe-snizhenie/.
16. Yakhno N.N., Koberskaya N.N., Zakharov V.V., Grishina D.A., Lokshina A.B., Mkhitaryan E.A. et al. The Influence of age, Comorbide Cardiovascular and Emotional Factors on Subtle Cognitive Decline in Average, Elderly and Old Age. Nevrologicheskiy Zhurnal= Neurological Journal. 2018;23(6):309–315. (in Russ) Available at: http://www.medlit.ru/journalsview/nevrojournal/view/journal/2018/issue-6/365-vliyanie-vozrasta-komorbidnyh-serdechno-sosudistyh-i-emocional-nyh-faktorov-na-legkoe-kognitivnoe-snizhenie-v-srednem-pozhilom-i-starcheskom-vozraste/.
17. Lokshina A.B. Modern Aspects of Diagnosis and Treatment of Mild Cognitive Impairment. Rossiyskiy zhurnal geriatricheskoy meditsiny = Russian Journal of Geriatric Medicine. 2020;(3):199–204. doi: 10.37586/2686-86363-2020-199-204.
18. Yakhno N.N., Lokshina A.B., Zakharov V.V., Grishina D.A., Koberskaya N.N., Mkhitaryan E.A. Mild Cognitive Impairment in Russian Population. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(5):179–180. doi: 10.17116/jnevro201911905S.
19. Heiss W.-D., Rosenberg G.A., Thiel A., Berlot R., de Reuck J. Neuroimaging in Vascular Cognitive Impairment: A State-of-the-Art Review. BMC Med. 2016;14(1):174. doi: 10.1186/s12916-016-0725-0.
20. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5 th ed. London: American Psychiatric Association; 2013. 991 p. doi: 10.1176/appi.books.9780890425596.
21. Rostamian S., Mahinrad S., Stijnen T., Sabayan B., de Craen A.J.M. Cognitive impairment and risk of stroke: a systematic review and meta-analysis of prospective cohort studies. Stroke. 2014;45(5):1342–1348. doi: 10.1161/STROKEAHA.114.004658.
22. Sudo F.K., Amado P., Alves G.S., Laks J., Engelhardt E. A Continuum of Executive Function Deficits in Early Subcortical Vascular Cognitive Impairment: A Systematic Review and Meta-Analysis. Dement Neuropsychol. 2017;11(4):371–380. doi: 10.1590/1980-57642016dn11-040006.
23. Taylor W.D., Aizenstein H.J., Alexopoulos G.S. The Vascular Depression Hypothesis: Mechanisms Linking Vascular Disease with Depression. Mol Psychiatry. 2013;18(9):963–974. doi: 10.1038/mp.2013.20.
24. Schmidt W., Endres M., Dimeo F., Jungehulsing G.J. Train the Vessel, Gain the Brain: Physical Activity and Vessel Function and the Impact on Stroke Prevention and Outcome in Cerebrovascular Disease. Cerebrovasc Dis. 2013;35(4):303–312. doi: 10.1159/000347061.
25. Giuli C., Fattoretti P., Gagliardi C., Mocchegiani E., Venarucci D., Balietti M. et al. My Mind Project: the Effects of Cognitive Training for Elderly – the Study Protocol of a Prospective Randomized Intervention Study. Aging Clin Exp Res. 2017;(29):353–360. doi: 10.1007/s40520-016-0570-1.
26. Martínez-Lapiscina E.H., Clavero P., Toledo E., Estruch R., Salas-Salvadó J., San Julián B. et al. Mediterranean Diet Improves Cognition: the PREDIMED-NAVARRA Randomised Trial. J Neurol Neurosurg Psychiatry. 2013;84(12):1318–1325. doi: 10.1136/jnnp-2012-304792.
27. Rodakowski J., Saghafi E., Butters M.A., Skidmore E.R. Non-Pharmacological Interventions for Adults with Mild Cognitive Impairment and Early Stage Dementia: An Updated Scoping Review. Mol Aspects Med. 2015;43–44:38–53. doi: 10.1016/j.mam.2015.06.003.
28. Naumenko A.A., Preobrazhenskaya I.S. Cognitive and Motor Training for Patients with Moderate Cognitive Impairment and Mild Dementia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):81–87. doi: 10.14412/20742711-2018-4-81-87.
29. Ngandu T., Lehtisalo J., Solomon A., Levälahti E., Ahtiluoto S., Antikainen R. et al. A 2 Year Multidomain Intervention of Diet, Exercise, Cognitive Training, and Vascular Risk Monitoring Versus Control to Prevent Cognitive Decline in At-Risk Elderly People (FINGER): A Randomised Controlled Trial. Lancet. 2015;385(9984):2255–2263. doi: 10.1016/S0140-6736(15)60461-5.
30. Trompet S., van Vliet P., de Craen A.J.M., Jolles J., Buckley B.M., Murphy M.B. et al. Pravastatin and Cognitive Function in the Elderly: Results of the PROSPER Study. J Neurol. 2010;257(1):85–90. doi: 10.1007/s00415-0095271-7.
31. Price J.F., Stewart M.C., Deary I.J., Murray G.D., Sandercock P., Butcher I. et al. Low Dose Aspirin and Cognitive Function in Middle Aged to Elderly Adults: Randomized Controlled Trial. BMJ. 2008;337:a1198. doi: 10.1136/bmj.a1198.
32. Areosa S.A., Sherriff F., McShane R. Memantine for Dementia. Cochrane Database Syst Rev. 2005;(3):CD003154. doi: 10.1002/14651858.CD003154.pub4.
33. Qaseem A., Snow V., Cross J.T. Jr, Forciea M.A., Hopkins R. Jr, Shekelle P. et al. Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370–378. doi: 10.7326/0003-4819-148-5-200803040-00008.
34. Rockwood K., Mitnitski A., Black S.E., Richard M., Defoy I. Cognitive Change in Donepezil Treated Patients with Vascular or Mixed Dementia. Can J Neurol Sci. 2013;40(4):564–571. doi: 10.1017/s0317167100014670.
35. Russ T.C., Morling J.M. Cholinesterase Inhibitors for Mild Cognitive Impairment. Cochrane Database Syst Rev. 2012(9):CD009132. doi: 10.1002/14651858.CD009132.pub2.
36. Diniz B.S., Pinto J.A. Jr, Gonzaga M.L., Guimarães F.M., Gattaz W.F., Forlenza O.V. To Treat or Not to Treat? A Meta-Analysis of the Use of Cholinesterase Inhibitors in Mild Cognitive Impairment for Delaying Progression to Alzheimer’s Disease. Eur Arch Psychiatry Clin Neurosci. 2009;259(4):248–256. doi: 10.1007/s00406-008-0864-1.
37. Ahlemeyer B., Krieglesytain J. Neuroprotective Effects of Gingko Biloba. Cell Mol Life Sci. 2003;60:1779–1792. doi: 10.1007/s00018-003-3080-1.
38. Abdel-Kader R., Hauptmann S., Keil U., Scherping I., Leuner K., Eckert A., Müller W.E. Stabilization of Mitochondrial Function by Ginkgo Biloba Extract (EGb 761). Pharmacol Res. 2007;56(6):493–502. doi: 10.1016/j.phrs.2007.09.011.
39. Tchantchou F., Xu Y., Wu Y., Christen Y., Luo Y. EGb 761 Enhances Adult Hippocampal Neurogenesis and Phosphorylation of CREB in Transgenic Mouse Model of Alzheimer’s Disease. FASEB J. 2007;21:2400–2408. doi: 10.1096/fj.06-7649com.
40. Zhang S.J., Xue Z.Y. Effect of Western Medicine Therapy Assisted by Ginkgo Biloba Tablet on Vascular Cognitive Impairment of None Dementia. Asian Pac J Trop Med. 2012;5(8):661–664. doi: 10.1016/S19957645(12)60135-7.
41. Yakhno N.N., Zakharov V.V., Lokshina AB, Gavrilova S.I., Fedorova Ya.B., Gustov A.V. et al. Tanakan (EGb761) in the Treatment of Moderate Cognitive Impairment (Multicenter Study). Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2006;(12):41–46. (In Russ).
42. Weinmann S., Roll S., Schwarzbach C., Vauth C., Willich S.N. Effects of Ginkgo Biloba in Dementia: Systematic Review and Meta-Analysis. BMC Geriatr. 2010;10:14. doi: 10.1186/1471-2318-10-14.
43. Zhang H.F., Huang L.B., Zhong Y.B., Zhou Q.H., Wang H.L., Zheng G.Q., Lin Y. An Overview of Systematic Reviews of Ginkgo Biloba Extracts for Mild Cognitive Impairment and Dementia. Front Aging Neurosci. 2016;8:276. doi: 10.3389/fnagi.2016.00276.
44. Tan M.S., Yu J.T., Tan C.C., Wang H.F., Meng X.F., Wang C. et al. Efficacy and Adverse Effects of Ginkgo Biloba for Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2015;43(2):589–603. doi: 10.3233/JAD-140837.
45. Amieva H., Meillon C., Helmer C., Barberger-Gateau P., Dartigues J.F. Gingko Biloba Extract and Long Term Cognitive Decline: A 20 Years Follow Up Population Based Study. PLoS One. 2013;8(1):e52755. doi: 10.1371/journal.pone.0052755.
Review
For citations:
Grishina DA, Lokshina AB. Diagnosis and treatment of vascular cognitive impairments. Meditsinskiy sovet = Medical Council. 2021;(2):45-54. (In Russ.) https://doi.org/10.21518/2079-701X-2021-2-45-54
Views:
717
Email this article 